source
- Intellia’s CRISPR therapy cuts hereditary angioedema attacks by 87% in Phase 3 trialIntellia Therapeutics reported that its experimental CRISPR-based drug lonvo-z met the primary endpoint in a Phase 3 study for hereditary angioedema, a rare swelling disorder. The trial showed an…
- Intellia's in-body CRISPR therapy achieves first Phase 3 successIntellia announced that its experimental in vivo CRISPR gene‑editing therapy has completed a Phase 3 trial with positive results. This is the first instance of a CRISPR‑based treatment delivered d…